Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMMODITIES: Dual Combination Therapy vs Monotherapy in PAH with Cardiovascular Comorbidities
NCT07245680Phase 3Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2026
- Primary completion
- Feb 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ambrisentan in pulmonary arterial hypertension (PAH), sponsored by Assistance publique - Hôpitaux de Paris. Started Apr 2026; status: recruiting.
02
Drugs
ambrisentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT07245680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07245680.